Abstract: Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.

Abstract: Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.

Abstract: Systems for assessing and documenting changes in handwriting neurologic toxicity adverse events associated with a medical treatment (e.g., immune effector cell therapy) comprise a handwriting neurotoxicity grading criteria that defines the symptoms of at least one adverse event including micrographia, dysgraphia and agraphia. The handwriting neurotoxicity grading criteria may be included in a system for assessing immune effector cell associated movement and neurocognitive disorder, that comprises grading criteria for one or more of the symptom domains: handwriting impairment, gait impairment, other movement abnormalities of extremities, impairment in ability to perform ADLs, and impairment in expression or motivation.